IONS (Ionis Pharmaceuticals, Inc.) SVB Leerink boosted their earnings-per-share expectations for Ionis Pharmaceuticals for the fourth quarter of 2022 in a research note published on Wednesday, November 30th. M. Foroohar of SVB Leerink anticipates that the company will earn $1.344 per share for the quarter, an increase from the prior earnings of $2.988 per share. The current rating for SVB Leerink is “Market Perform,” and the price target is $26.00. Ionis Pharmaceuticals is anticipated to generate $2.61 per share earnings for the fiscal year. According to estimates provided by SVB Leerink, Ionis Pharmaceuticals should generate earnings of $2.58 per share for the fiscal year 2023.

The NASDAQ: IONS stock started the trading day at $40.20. The stock price has a moving average of $43.73 over the past fifty days, while its moving average over the past 200 days is $41.33. There is a debt-to-equity ratio of 2.10, the current ratio is 7.59, the quick ratio is 7.52, and the current ratio is 7.59. The price of Ionis Pharmaceuticals has ranged from a low of $25.04 to a high of $48.82 over the past 52 weeks.
The IONS have been cited in a variety of other papers as well. Ionis Pharmaceuticals received a “sell” rating from Citigroup in a research report published on Thursday, November 10th. Additionally, the target price that the firm has set for the stock increased from $28.00 to $31.00. Morgan Stanley gave Ionis Pharmaceuticals an “overweight” rating in a research report published on Thursday, November 10th. The price objective that the investment bank had previously set for the stock was reduced from $57.00 to $56.00. Ionis Pharmaceuticals was included as a company that StockNews.com will cover in a report released on October 12th. They decided to maintain their “hold” rating for the company. Barclays increased their price objective on Ionis Pharmaceuticals to $44.00 and announced it in a research report that was made public on Tuesday, November 15th. Piper Sandler increased their price objective on Ionis Pharmaceuticals from $58.00 to $60.00 in a report published on Wednesday, November 9th. Two equity research analysts recommend selling the stock, two recommend holding onto the stock, and six recommend buying the stock. According to Bloomberg.com, the consensus recommendation for Ionis Pharmaceuticals is to “Hold” the stock, and the consensus price objective is $46.80.

Institutional investors and hedge funds have recently been active in the company’s stock market, buying and selling shares. DURING THE SECOND QUARTER, price T. Rowe Associates Inc. (MD) made a 4.9% investment increase in Ionis Pharmaceuticals. Price T. Rowe Associates Inc. now owns 15,056,046 shares of the company’s stock, which is valued at $557,375,000. This is the result of the company making an additional purchase of 705,586 shares during the period. Vanguard Group Inc. boosted its holdings in Ionis Pharmaceuticals by 5.0 percent during the third quarter of this fiscal year. After making additional purchases during the time frame in question, Vanguard Group Inc. now holds 12,806,023 shares of the company’s stock, currently valued at $566,411,000. Ionis Pharmaceuticals was the beneficiary of a 10.1% rise in Clearbridge Investments LLC’s interest in the company during the first quarter. Clearbridge Investments LLC now has 6,476,033 shares of the company’s stock, valued at $239,872,000 following the acquisition of an additional 593,051 shares during the time in question. During the first three months of 2018, Tweedy Browne Co. LLC invested about 108,346,000 dollars in acquiring a new position in Ionis Pharmaceuticals.
Last but not least, BVF Inc. boosted its holdings in Ionis Pharmaceuticals by 125.1% during the third quarter of the fiscal year. BVF Inc. IL now has a total of 2,872,953 shares of the company’s stock, which is worth a total of $127,071,000 following the acquisition of an additional 1,596,379 shares during the most recent fiscal quarter. The company’s stock is owned by institutional investors and hedge funds to 79.31% of the total.

Ionis Pharmaceuticals, Inc. is a firm established in the United States that specializes in developing RNA-targeted therapies. Spinraza, an injection used to treat polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis, and Waylivra, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy, are offered by the company. Spinraza is administered via injection. Waylivra is administered by mouth.

The post SVB Leerink issued an earnings forecast for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) for the fourth quarter of 2022. appeared first on Best Stocks.